- Open Access
Genomic studies of mood disorders - the brain as a muscle?
Genome Biology volume 6, Article number: 215 (2005)
Recent genomic studies showing abnormalities in the fibroblast growth factor system in the postmortem brains of people with major depressive disorder support previous indications of a role for growth factors in mood disorders. Similar molecular pathways, volumetric changes, and the effects of exercise on mood suggest a superficial analogy, and perhaps a deeper relationship, between muscle and brain functioning.
An evolutionary perspective on mood disorders
Mood - the way one feels inside emotionally - is likely to have evolved, broadly speaking, as a sensor and integrator of the environmental availability, or lack of availability, of resources that an organism needs to live, to develop and to propagate its genes. A non-nurturing, hostile environment engenders low mood and depression. This is useful in making the organism conserve existing resources, keep still and stay out of harm's way [1, 2]. Conversely, a nurturing, favorable environment engenders high mood and euphoria, making the organism more likely to take advantage of opportunities, to expand and to propagate its genes. The switch from low to high mood becomes loose in bipolar (manic-depressive) illness, and overreacts to minor stimuli in an excessive and persistent fashion that often obscures any correlation with external events that trigger the switch. The incongruence between mood and environment is a hallmark of severe clinical depression or mania. In severe clinical depression (also called major depressive disorder), mood is low even in favorable conditions, whereas in mania, mood is high even in unfavorable conditions. Extremes of mood are often associated with cognitive distortions (psychotic symptoms).
Mood disorders have been studied primarily in humans, although aspects of them can be found in other animals and can be studied in rodent models, for example . They are the result of a complex interaction between genes and the environment, and some people are more susceptible than others, whether for genetic or other reasons (such as developmental insults or stressors). Little is currently known about the genes involved in susceptibility to mood disorders . Brain-imaging studies have shown that the regions of the brain that are important in mood regulation include the prefrontal cortex and the hippocampus, and depression has been linked with a decrease in volume of these parts of the brain. Depression can be treated with a range of antidepressant drugs, including specific serotonin re-uptake inhibitors (SSRIs such as fluoxetine, one brand name for which is Prozac, sertraline (Zoloft), or paroxetine (Paxil)). A recent study  of gene expression in the brains of people with major depression gives some insights into the genes involved in this disorder.
Depression and decreased growth factors
Evans et al.  used Affymetrix microarrays to study gene-expression patterns in the prefrontal cortex of postmortem human brains, focusing on subjects with depression, bipolar disorder or no psychiatric disorder. They uncovered a down-regulation of members of the fibroblast growth factor (FGF) family and their receptors - with the major factors being FGF1 and FGF2 and the receptors FGFR2 and FGFR3 - in subjects with depression but not in the other brains. A history of antidepressant treatment with SSRIs in the depressed subjects seemed to mitigate this decrease in FGFs and FGF receptors, especially for FGF2, FGFR2 and FGFR3.
The connection between FGFs and depression is particularly interesting in light of the postulated involvement of FGF2 in the cognitive and neurotrophic effects of nicotine  and the increased use of cigarettes, possibly as a means of self-medication, in people with depression and schizophrenia . Moreover, recent work in rats has shown that a combination of the SSRI antidepressant fluoxetine and the atypical antipsychotic drug olanzapine, which appear in human studies to be more effective for the treatment of resistant depression in combination than individually, led to increased levels of FGF2 mRNA in prefrontal cortex, as well as in hippocampus and striatum . Overall, the results of Evans et al.  are consistent with a body of work in vitro and in animal models showing that antidepressant and mood-stabilizer treatments increase the levels of neurotrophic and cell-survival factors in the brain [9–12]. It is of interest that the subjects with bipolar disorder in the study  did not show a similar decrease in components of the FGF system to that seen in depressive subjects; this suggests that the decrease might be specific to the depressive state and leaves open the possibility that the opposite may be true - that FGFs may be increased - in more manic states, giving an overall mixed picture in brains from bipolar patients.
As a caveat, Evans et al.  present data from a relatively small number of subjects; this is typical of the human postmortem work published so far and is due to the scarcity of good-quality tissue with adequate associated phenotypic information. The first cohort contained 9 depression, 6 bipolar and 7 control subjects; the second contained 4 depressed and 6 control subjects. Generally, given the genetic heterogeneity of human populations and the differences in exposures to environmental factors (including psychotropic drugs) in the lifetimes of different people, work with postmortem human brains needs as high a number of subjects as possible. Careful cross-validation with multiple other independent lines of evidence is also needed, including 'clean' animal model gene-expression data and data on human genetic linkage; my colleagues and I have termed this cross-validation approach 'expanded convergent functional genomics' .
A second caveat that should be borne in mind when looking at the work of Evans et al.  is that it looks predominantly at male postmortem brain samples; also, the samples are often the result of violent death by suicide or accident. One question that needs further study is whether there are differences in the gene-expression patterns and resulting neurobiology of depression between men and women. Clinical epidemiology studies have consistently shown that there is a two-fold higher incidence of depression in women than in men. The phenomenology and environmental triggers of depression and suicidality may be somewhat different in the two sexes - loss of status leading to violent completed suicides in men, and perceived abandonment leading to incomplete attempted suicides by women [1, 13, 14].
Other work  has shown that another growth factor, brain-derived neurotrophic factor (BDNF), is decreased in depression, and it may also be involved in bipolar disorders and schizophrenia, though this is less clear. Interestingly, the work of Evans et al.  also found that levels of the BDNF receptor Ntrk2 were significantly decreased in depressed subjects. Other growth factors have been implicated in psychiatric illnesses: nerve growth factor , epidermal growth factor , and neurotrophin 3 . Decreased levels of growth factors are also associated with decreased brain volume in key areas for psychiatric illness, such as the hippocampus [18, 19].
Circumstantial evidence suggests that, conversely, an excess of growth-factor activity might be correlated with mania. FGFR1 and IGF1 (insulin-like growth factor 1) were elevated in an animal model of mania . Anabolic steroids, which not only increase muscle mass but also increase the levels of growth factors such as insulin-like growth factor 1 in many parts of the body , also have effects similar to (hypo) mania, such as elevation of mood, hypersexuality and promotion of aggression [22, 23]. Physical exercise and an enriched environment, both of which can have mood-elevating effects, have been shown in mouse studies to increase proliferation of hippocampal stem cells [24–26], presumably through increased levels and activity of growth factors .
Parallels between the regulation of mood and muscle development
FGFs are believed to be important for the differentiation and maturation of many tissues, including muscle. The developmentally regulated expression and distribution of FGFRs, especially FGFR3, play a role in muscle maturation . The fact that a molecular signaling system used for muscle and connective-tissue development has been shown to be downregulated in depression raises the intriguing possibility that brain regions involved in mood are regulated in an analogous way to muscle; for instance, that these regions are atrophied in depressed people in the same way that muscle atrophies when it is inactive for long periods. In both brain and muscle, tissue volume and levels of activity seem to correlate with levels of growth factors, and sometimes the same growth factors are involved in both tissues. It is unclear whether depression occurs because of low growth-factor levels in key brain areas or whether the growth-factor levels are low because those brain areas are less active. Both may be true in varying degrees, and the role of environmental stress as a precipitant cannot be overemphasized . Identifying functional polymorphisms in genes of the FGF system in subjects with depression may point to a genetic or hereditary component. Regardless of which phenomenon is the cause and which the result, the mood-regulating brain regions appear to shrink the longer the person stays in the depressed state  - just as muscles shrink when they are unused. Following from the evolutionary perspective outlined above, we can speculate that atrophy of brain regions in depression may be adaptive mechanisms to a chronically deprived and limiting environment, whereas conversely hypertrophy of brain and elevated mood would be adaptive reactions to a supportive and resource-rich environment (Figure 1). The same growth factors may be used in both brain and muscle because evolution is a tinkerer and uses the building blocks that are available.
This analogy has practical implications. The selective short-term use of steroids with anabolic properties might be useful for treating severe depression, albeit as a heroic measure of last resort to jump-start recovery, on a par with electroconvulsive therapy. Moreover, from a more practical standpoint, the analogy suggests that imaging studies that measure the volume of different brain regions  could be used for assessing the severity of mood disorders and the response to treatment. Last but not least, what is good for muscle - physical exercise - seems to be good for the brain too . Physical therapy may become a useful supplement to pharmacotherapy and psychotherapy, with a treadmill supplanting the proverbial Freudian couch. The Romans may have had it right with their ideal of mens sana in corpore sano (a healthy mind in a healthy body).
Niculescu AB, Akiskal HS: Proposed endophenotypes of dysthymia: evolutionary, clinical and pharmacogenomic considerations. Mol Psychiatry. 2001, 6: 363-366. 10.1038/sj.mp.4000906.
Nesse RM: Natural selection and the elusiveness of happiness. Philos Trans R Soc Lond B Biol Sci. 2004, 359: 1333-1347. 10.1098/rstb.2004.1511.
Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB, Kuczenski R, Niculescu AB: Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol Psychiatry. 2004, 9: 1007-1029. 10.1038/sj.mp.4001547.
Kelsoe JR, Niculescu AB: Finding genes for bipolar disorder in the functional genomics era: from convergent functional genomics to phenomics and back. CNS Spectr. 2002, 7: 215-226.
Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, Tomita H, Lopez JF, Thompson RC, Meng F, Stead JD, et al: Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA. 2004, 101: 15506-15511. 10.1073/pnas.0406788101.
Bellurado N, Mudo G, Blum M, Itoh N, Agnati L, Fuxe K: Nicotine-induced FGF-2 mRNA in rat brain is preserved during aging. Neurobiol Aging. 2004, 25: 1333-1342. 10.1016/j.neurobiolaging.2004.01.002.
Spring B, Pingitore R, McChargue DE: Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed, and nonpatient smokers. Am J Psychiatry. 2003, 160: 316-322. 10.1176/appi.ajp.160.2.316.
Maragnoli ME, Fumagalli F, Gennarelli M, Racagni G, Riva MA: Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry. 2004, 55: 1095-1102. 10.1016/j.biopsych.2004.02.003.
Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997, 54: 597-606.
Manji HK, Duman RS: Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull. 2001, 35: 5-49.
Kodama M, Fujioka T, Duman RS: Chronic olanzapine or fluoxe-tine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004, 56: 570-580. 10.1016/j.biopsych.2004.07.008.
Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T, Meuth S, Nagy A, Greene RW, Nestler EJ: Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA. 2004, 101: 10827-10832. 10.1073/pnas.0402141101.
Niculescu AB, Akiskal HA: Sex hormones, Darwinism, and depression. Arch Gen Psychiatry. 2001, 58: 1083-1084. 10.1001/archpsyc.58.11.1083-a.
Hasler G, Drevets WC, Manji HK, Charney DS: Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004, 29: 1765-1781. 10.1038/sj.npp.1300506.
Parikh V, Evans DR, Khan MM, Mahadik SP: Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res. 2003, 60: 117-123. 10.1016/S0920-9964(02)00434-6.
Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K, Someya T, Kakita A, Takahashi H, Nawa H: Abnormal expression of epidermal growth factor and its receptor in the fore-brain and serum of schizophrenic patients. Mol Psychiatry. 2002, 7: 673-682. 10.1038/sj.mp.4001081.
Hattori M, Kunugi H, Akahane A, Tanaka H, Ishida S, Hirose T, Morita R, Yamakawa K, Nanko S: Novel polymorphisms in the promoter region of the neurotrophin-3 gene and their associations with schizophrenia. Am J Med Genet. 2002, 114: 304-309. 10.1002/ajmg.10248.
Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, et al: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003, 112: 257-269. 10.1016/S0092-8674(03)00035-7.
Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, Egan MF, Meyer-Lindenberg A, Weinberger DR: The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci. 2004, 24: 10099-10102. 10.1523/JNEUROSCI.2680-04.2004.
Niculescu AB, Segal DS, Kuczenski R, Barrett T, Hauger RL, Kelsoe JR: Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol Genomics. 2000, 4: 83-91.
Aberg MA, Aberg ND, Palmer TD, Alborn AM, Carlsson-Skwirut C, Bang P, Rosengren LE, Olsson T, Gage FH, Eriksson PS: IGF-I has a direct proliferative effect in adult hippocampal progenitor cells. Mol Cell Neurosci. 2003, 24: 23-40. 10.1016/S1044-7431(03)00082-4.
Daly RC, Su TP, Schmidt PJ, Pagliaro M, Pickar D, Rubinow DR: Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology. 2003, 28: 317-331. 10.1016/S0306-4530(02)00025-2.
Hartgens F, Kuipers H: Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004, 34: 513-554.
van Praag H, Christie BR, Sejnowski TJ, Gage FH: Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci USA. 1999, 96: 13427-13431. 10.1073/pnas.96.23.13427.
van Praag H, Kempermann G, Gage FH: Neural consequences of environmental enrichment. Nat Rev Neurosci. 2000, 1: 191-198. 10.1038/35044558.
Kempermann G, Gast D, Gage FH: Neuroplasticity in old age: sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol. 2002, 52: 135-143. 10.1002/ana.10262.
Vaynman S, Ying Z, Gomez-Pinilla F: Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci. 2004, 20: 2580-2590. 10.1111/j.1460-9568.2004.03720.x.
Sogos V, Balaci L, Ennas MG, Dell'era P, Presta M, Gremo F: Developmentally regulated expression and localization of fibroblast growth factor receptors in the human muscle. Dev Dyn. 1998, 211: 362-373. 10.1002/(SICI)1097-0177(199804)211:4<362::AID-AJA7>3.0.CO;2-F.
Pizarro JM, Lumley LA, Medina W, Robison CL, Chang WE, Alagappan A, Bah MJ, Dawood MY, Shah JD, Mark B, et al: Acute social defeat reduces neurotrophin expression in brain cortical and subcortical areas in mice. Brain Res. 2004, 1025: 10-20. 10.1016/j.brainres.2004.06.085.
Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, Raichle ME: Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997, 386: 824-827. 10.1038/386824a0.
Botteron KN, Raichle ME, Drevets WC, Heath AC, Todd RD: Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatry. 2002, 51: 342-344. 10.1016/S0006-3223(01)01280-X.
Brosse AL, Sheets ES, Lett HS, Blumenthal JA: Exercise and the treatment of clinical depression in adults: recent findings and future directions. Sports Med. 2002, 32: 741-760.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Niculescu, A.B. Genomic studies of mood disorders - the brain as a muscle?. Genome Biol 6, 215 (2005) doi:10.1186/gb-2005-6-4-215
- Bipolar Disorder
- Mood Disorder
- Major Depressive Disorder
- Fibroblast Growth Factor Receptor
- Postmortem Human Brain